Innovative developments and emerging technologies in RNA therapeutics

References

• Zamecnik PC, Stephenson ML. Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Nat Acad Sci. 1978;75:280–284.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Liang XH, and Baker BF, et al. Antisense Technology: a Review. J Biol Chem. 2021;296 100416 .
   PubMed Web of Science ®Google Scholar
• Shen X, Corey DR. Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs. Nucleic Acids Res. 2018;46:1584–1600.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Witztum JL, Bennett CF, et al. RNA-Targeted Therapeutics. Cell Metab. 2018;27:714–739.
   PubMed Web of Science ®Google Scholar
• O’Rourke JR, Swanson MS. Mechanisms of RNA-mediated disease. J Biol Chem. 2009;284:7419–7423.
   PubMed Web of Science ®Google Scholar
• Bartel DP. MicroRNAs: target recognition and regulatory functions. Cell. 2009;136:215–233.
   PubMed Web of Science ®Google Scholar
• Havens MA, Hastings ML. Splice-switching antisense oligonucleotides as therapeutic drugs. Nucleic Acids Res. 2016;44:6549–6563.
   PubMed Web of Science ®Google Scholar
• Havens MA, Duelli DM, Hastings ML. Targeting RNA splicing for disease therapy. Wiley Interdiscip Rev RNA. 2013;4(3):247–266.
   PubMed Web of Science ®Google Scholar
• Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov. 2010;9:537–550.
   PubMed Web of Science ®Google Scholar
• Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nat Rev Drug Discov. 2020;19:673–694.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Wang S, Vickers TA, et al. Cellular uptake and trafficking of antisense oligonucleotides. Nat Biotechnol. 2017;35:230–237.
   PubMed Web of Science ®Google Scholar
• Iwamoto N, Butler DCD, Svrzikapa N, et al. Control of phosphorothioate stereochemistry substantially increases the efficacy of antisense oligonucleotides. Nat Biotechnol. 2017;35:845–851.
   PubMed Web of Science ®Google Scholar
• Featherston AL, Kwon Y, Pompeo MM, et al. Catalytic asymmetric and stereodivergent oligonucleotide synthesis. Science. 2021;371:702–707.
   PubMed Web of Science ®Google Scholar
• Li M, Lightfoot HL, Halloy F, et al. Synthesis and cellular activity of stereochemically-pure 2’-O-(2-methoxyethyl)-phosphorothioate oligonucleotides. Chem Comm. 2017;53:541–544.
   PubMed Web of Science ®Google Scholar
• Østergaard ME, De Hoyos CL, Wan WB, et al. Understanding the effect of controlling phosphorothioate chirality in the DNA gap on the potency and safety of gapmer antisense oligonucleotides. Nucleic Acids Res. 2020;48:1691–1700.
   PubMed Web of Science ®Google Scholar
• Byrne M, Vathipadiekal V, Apponi L, et al. Stereochemistry enhances potency. Efficacy, and Durability of Malat1 Antisense Oligonucleotides in Vitro and in Vivo in Multiple Species Translational Vision Sci Technol. 2021;10:23.
   Google Scholar
• Dragovich PS, Adhikari P, Blake RA, et al. Antibody-mediated delivery of chimeric protein degraders which target estrogen receptor alpha (ERα). Bioorg Med Chem Lett. 2020;30:126907.
   PubMed Web of Science ®Google Scholar
• Goyenvalle A, Griffith G, Babbs A, et al. Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers. Nat Med. 2015;21:270–275.
   PubMed Web of Science ®Google Scholar
• Geary RS. Antisense oligonucleotide pharmacokinetics and metabolism. Expert opinion on drug metabolism & toxicology . 2009;5:381–391.
   PubMed Web of Science ®Google Scholar
• Nishina K, Piao W, Yoshida-Tanaka K, et al. DNA/RNA heteroduplex oligonucleotide for highly efficient gene silencing. Nat Commun. 2015;6:7969.
   PubMed Web of Science ®Google Scholar
• Yoshioka K, Kunieda T, Asami Y, et al. Highly efficient silencing of microRNA by heteroduplex oligonucleotides. Nucleic Acids Res. 2019;47:7321–7332.
   PubMed Web of Science ®Google Scholar
• Ono D, Asada K, Yui D, et al. Separation-related rapid nuclear transport of DNA/RNA heteroduplex oligonucleotide: unveiling distinctive intracellular trafficking. Molecular Therapy - Nucleic Acids. 2021;23:1360–1370.
   Google Scholar
• Kuwahara H, Song J, Shimoura T, et al. Modulation of blood-brain barrier function by a heteroduplex oligonucleotide in vivo. Sci Rep. 2018;8:4377.
   PubMed Web of Science ®Google Scholar
• Nagata T, Dwyer CA, Yoshida-Tanaka K, et al. Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS. Nat Biotechnol. 2021;39:1529–1536.
   PubMed Web of Science ®Google Scholar
• Zahid M, Robbins P. Cell-Type specific penetrating peptides: therapeutic promises and challenges. Molecules. 2015;20:13055.
   PubMed Web of Science ®Google Scholar
• Pae J, Pooga M. Peptide-mediated delivery: an overview of pathways for efficient internalization. Ther Deliv. 2014;5:1203–1222.
   PubMedGoogle Scholar
• Tung C-H, Stein S. Preparation and applications of peptide− oligonucleotide conjugates. Bioconjug Chem. 2000;11:605–618.
   PubMed Web of Science ®Google Scholar
• Prater CE, Miller PS. 3 ‘-methylphosphonate-modified oligo-2 ‘-O-methylribonucleotides and their Tat peptide conjugates: uptake and stability in mouse fibroblasts in culture. Bioconjug Chem. 2004;15:498–507.
   PubMed Web of Science ®Google Scholar
• Turner JJ, Arzumanov AA, Gait MJ. Synthesis, cellular uptake and HIV-1 Tat-dependent trans-activation inhibition activity of oligonucleotide analogues disulphide-conjugated to cell-penetrating peptides. Nucleic Acids Res. 2005;33:27–42.
   PubMed Web of Science ®Google Scholar
• Eguchi A, Meade BR, Chang Y-C, et al. Efficient siRNA delivery into primary cells by a peptide transduction domain–dsRNA binding domain fusion protein. Nat Biotechnol. 2009;27:567–571.
   PubMed Web of Science ®Google Scholar
• Meade BR, Gogoi K, Hamil AS, et al. Efficient delivery of RNAi prodrugs containing reversible charge-neutralizing phosphotriester backbone modifications. Nat Biotechnol. 2014;32:1256–1261.
   PubMed Web of Science ®Google Scholar
• Knerr L, Prakash TP, Lee R, et al. Glucagon like peptide 1 receptor agonists for targeted delivery of antisense oligonucleotides to pancreatic beta cell. J Am Chem Soc. 2021;143:3416–3429.
   PubMed Web of Science ®Google Scholar
• Sugo T, Terada M, Oikawa T, et al. Development of antibody-siRNA conjugate targeted to cardiac and skeletal muscles. J Control Release. 2016;237:1–13.
   PubMed Web of Science ®Google Scholar
• Arnold A, Malek-Adamian E, and Le P, et al. Antibody-antisense oligonucleotide conjugate downregulates a key gene in glioblastoma stem cells. Mol Ther Nucleic Acids. 2018;11:187–194.
   Google Scholar
• Satake N, Duong C, Yoshida S, et al. Novel targeted therapy for precursor b cell acute lymphoblastic leukemia: anti-cd22 antibody-mxd3 antisense oligonucleotide conjugate. Mol Med. 2016;22:632–642.
   PubMed Web of Science ®Google Scholar
• Zavoiura O, Brunner B, Casteels P, et al. Nanobody–siRNA Conjugates for Targeted Delivery of siRNA to Cancer Cells. Mol Pharm. 2021;18:1048–1060.
   PubMedGoogle Scholar
• Debacker AJ, Voutila J, Catley M, et al. Delivery of oligonucleotides to the liver with galnac: from research to registered therapeutic drug. Mol Ther. 2020;28:1759–1771.
   PubMed Web of Science ®Google Scholar
• Orellana EA, Tenneti S, Rangasamy L, et al. FolamiRs: ligand-targeted, vehicle-free delivery of microRNAs for the treatment of cancer. Sci Transl Med. 2017;9. DOI:10.1126/scitranslmed.aam9327
   PubMed Web of Science ®Google Scholar
• Juliano RL. Intracellular trafficking and endosomal release of oligonucleotides: what we know and what we don’t. Nucleic Acid Ther. 2018;28:166–177.
   PubMed Web of Science ®Google Scholar
• Ming X, Carver K, Fisher M, et al. The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides. Nucleic Acids Res. 2013;41:3673–3687.
   PubMed Web of Science ®Google Scholar
• Yang B, Ming X, Cao C, et al. High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res. 2015;43:1987–1996.
   PubMed Web of Science ®Google Scholar
• Stein CA, Hansen JB, Lai J, et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 2010;38(1):e3–e3.
   PubMed Web of Science ®Google Scholar
• Brown CR, Gupta S, Qin J, et al. Investigating the pharmacodynamic durability of GalNAc–siRNA conjugates. Nucleic Acids Res. 2020;48:11827–11844.
   PubMed Web of Science ®Google Scholar
• Linnane E, Davey P, Zhang P, et al. Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines. Nucleic Acids Res. 2019;47:4375–4392.
   PubMed Web of Science ®Google Scholar
• Gilleron J, Querbes W, Zeigerer A, et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat Biotechnol. 2013;31:638–646.
   PubMed Web of Science ®Google Scholar
• Buntz A, Killian T, Schmid D, et al. Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression. Nucleic Acids Res. 2018;47:953–969.
   Web of Science ®Google Scholar
• He C, Migawa MT, Chen K, et al. High-resolution visualization and quantification of nucleic acid–based therapeutics in cells and tissues using Nanoscale secondary ion mass spectrometry (NanoSIMS). Nucleic Acids Res. 2020;49:1–14.
   Web of Science ®Google Scholar
• Crooke ST, Vickers TA, Liang X-H. Phosphorothioate modified oligonucleotide–protein interactions. Nucleic Acids Res. 2020;48:5235–5253.
   PubMed Web of Science ®Google Scholar
• Crooke ST, Seth PP, Vickers TA, et al. The interaction of phosphorothioate-Containing RNA targeted drugs with proteins is a critical determinant of the therapeutic effects of these agents. J Am Chem Soc. 2020;142:14754–14771.
   PubMed Web of Science ®Google Scholar
• Liang X-H, Sun H, Shen W, et al. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res. 2015;43:2927–2945.
   PubMed Web of Science ®Google Scholar
• Miller CM, Donner AJ, Blank EE, et al. Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res. 2016;44:2782–2794.
   PubMed Web of Science ®Google Scholar
• Wang S, Allen N, Vickers TA, et al. Cellular uptake mediated by epidermal growth factor receptor facilitates the intracellular activity of phosphorothioate-modified antisense oligonucleotides. Nucleic Acids Res. 2018;46:3579–3594.
   PubMed Web of Science ®Google Scholar
• Liang X-H, Sun H, Hsu C-W, et al. Golgi-endosome transport mediated by M6PR facilitates release of antisense oligonucleotides from endosomes. Nucleic Acids Res. 2019;48:1372–1391.
   Web of Science ®Google Scholar
• Vickers TA, Migawa MT, Seth PP, et al. Interaction of ASOs with PC4 Is highly influenced by the cellular environment and ASO chemistry. J Am Chem Soc. 2020;142:9661–9674.
   PubMed Web of Science ®Google Scholar
• Hyjek-Składanowska M, Vickers TA, Napiórkowska A, et al. Origins of the increased affinity of phosphorothioate-modified therapeutic nucleic acids for proteins. J Am Chem Soc. 2020;142:7456–7468.
   PubMed Web of Science ®Google Scholar
• Zimmermann TS, Karsten V, Chan A, et al. Clinical proof of concept for a novel hepatocyte-targeting GalNAc-siRNA conjugate. Mol Ther. 2017;25:71–78.
   PubMed Web of Science ®Google Scholar
• Balwani M, Sardh E, Ventura P, et al. Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria. N Engl J Med. 2020;382:2289–2301.
   PubMed Web of Science ®Google Scholar
• Garrelfs S, Frishberg Y, Hulton S, et al. LB002 Illuminate-A, a phase 3 study of Lumasiran, an investigational RNAi therapeutic, in children and adults with primary hyperoxaluria type 1 (PH1). Nephrol Dialysis Transplantation. 2020;35. DOI:10.1093/ndt/gfaa146.LB002
   Web of Science ®Google Scholar
• Raal FJ, Kallend D, Ray KK, et al. Inclisiran for the treatment of heterozygous familial hypercholesterolemia. N Engl J Med. 2020;382:1520–1530.
   PubMed Web of Science ®Google Scholar
• Osborn MF, Khvorova A. Improving siRNA delivery in vivo through lipid conjugation. Nucleic Acid Ther. 2018;28:128–136.
   PubMed Web of Science ®Google Scholar
• Wolfrum C, Shi S, Jayaprakash KN, et al. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs. Nat Biotechnol. 2007;25:1149–1157.
   PubMed Web of Science ®Google Scholar
• Biscans A, Coles A, Haraszti R, et al. Diverse lipid conjugates for functional extra-hepatic siRNA delivery in vivo. Nucleic Acids Res. 2018;47:1082–1096.
   Web of Science ®Google Scholar
• Hassler MR, Turanov AA, Alterman JF, et al. Comparison of partially and fully chemically-modified siRNA in conjugate-mediated delivery in vivo. Nucleic Acids Res. 2018;46:2185–2196.
   PubMed Web of Science ®Google Scholar
• Bartlett DW, Davis ME. Effect of siRNA nuclease stability on the in vitro and in vivo kinetics of siRNA-mediated gene silencing. Biotechnol Bioeng. 2007;97:909–921.
   PubMed Web of Science ®Google Scholar
• Layzer JM, McCaffrey AP, Tanner AK, et al. In vivo activity of nuclease-resistant siRNAs. RNA. 2004;10:766–771.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature. 2004;432:173–178.
   PubMed Web of Science ®Google Scholar
• Hu B, Zhong L, Weng Y, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5:101.
   PubMed Web of Science ®Google Scholar
• Allerson CR, Sioufi N, Jarres R, et al. Fully 2‘-Modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem. 2005;48:901–904.
   PubMed Web of Science ®Google Scholar
• Foster DJ, Brown CR, Shaikh S, et al. Advanced siRNA designs further improve in vivo performance of GalNAc-siRNA conjugates. Mol Ther. 2018;26:708–717.
   PubMed Web of Science ®Google Scholar
• Eckstein F. Phosphorothioates, essential components of therapeutic oligonucleotides. Nucleic Acid Ther. 2014;24:374–387.
   PubMed Web of Science ®Google Scholar
• Biscans A, Caiazzi J, Davis S, et al. The chemical structure and phosphorothioate content of hydrophobically modified siRNAs impact extrahepatic distribution and efficacy. Nucleic Acids Res. 2020;48:7665–7680.
   PubMed Web of Science ®Google Scholar
• Braasch DA, Jensen S, Liu Y, et al. RNA interference in mammalian cells by chemically-modified RNA. Biochemistry. 2003;42:7967–7975.
   PubMed Web of Science ®Google Scholar
• Shen W, De Hoyos CL, Sun H, et al. Acute hepatotoxicity of 2′ fluoro-modified 5–10–5 gapmer phosphorothioate oligonucleotides in mice correlates with intracellular protein binding and the loss of DBHS proteins. Nucleic Acids Res. 2018;46:2204–2217.
   PubMed Web of Science ®Google Scholar
• Sakamuri S, Eltepu L, Liu D, et al. Impact of phosphorothioate chirality on double-stranded siRNAs: a systematic evaluation of stereopure siRNA designs. Chembiochem. 2020;21:1304–1308.
   PubMed Web of Science ®Google Scholar
• Wu SY, Yang X, Gharpure KM, et al. 2’-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014;5:3459.
   PubMed Web of Science ®Google Scholar
• Kumar P, Parmar RG, Brown CR, et al. 5′-Morpholino modification of the sense strand of an siRNA makes it a more effective passenger. Chem Comm. 2019;55:5139–5142.
   PubMed Web of Science ®Google Scholar
• Ma JB, Yuan YR, Meister G, et al. Structural basis for 5’-end-specific recognition of guide RNA by the A. fulgidus Piwi protein. Nature. 2005;434:666–670.
   PubMed Web of Science ®Google Scholar
• Frank F, Sonenberg N, Nagar B. Structural basis for 5’-nucleotide base-specific recognition of guide RNA by human AGO2. Nature. 2010;465:818–822.
   PubMed Web of Science ®Google Scholar
• Bramsen JB, Pakula MM, Hansen TB, et al. A screen of chemical modifications identifies position-specific modification by UNA to most potently reduce siRNA off-target effects. Nucleic Acids Res. 2010;38:5761–5773.
   PubMed Web of Science ®Google Scholar
• Janas MM, Schlegel MK, Harbison CE, et al. Selection of GalNAc-conjugated siRNAs with limited off-target-driven rat hepatotoxicity. Nat Commun. 2018;9:723.
   PubMed Web of Science ®Google Scholar
• Malek-Adamian E, Fakhoury J, Arnold AE, et al. Effect of Sugar 2′,4′-modifications on gene silencing activity of siRNA duplexes. Nucleic Acid Ther. 2019;29:187–194.
   PubMed Web of Science ®Google Scholar
• Aurup H, Williams DM, Eckstein F. 2’-Fluoro and 2-amino-2’-deoxynucleoside 5’-triphosphates as substrates for T7 RNA polymerase. Biochemistry. 1992;31:9636–9641.
   PubMed Web of Science ®Google Scholar
• Mikami A, Erande N, Matsuda S, et al. Synthesis, chirality-dependent conformational and biological properties of siRNAs containing 5′-(R)- and 5′-(S)-C-methyl-guanosine. Nucleic Acids Res. 2020;48:10101–10124.
   PubMed Web of Science ®Google Scholar
• Akabane-Nakata M, Erande ND, Kumar P, et al. siRNAs containing 2′-fluorinated Northern-methanocarbacyclic (2′-F-NMC) nucleotides: in vitro and in vivo RNAi activity and inability of mitochondrial polymerases to incorporate 2′-F-NMC NTPs. Nucleic Acids Res. 2021;49:2435–2449.
   PubMed Web of Science ®Google Scholar
• Nanna AR, Kel’in AV, Theile C, et al. Generation and validation of structurally defined antibody–siRNA conjugates. Nucleic Acids Res. 2020;48:5281–5293.
   PubMed Web of Science ®Google Scholar
• Nuzzo S, Roscigno G, Affinito A, et al. Potential and challenges of aptamers as specific carriers of therapeutic oligonucleotides for precision medicine in cancer. Cancers (Basel). 2019;11:1521.
   PubMed Web of Science ®Google Scholar
• Klein D, Goldberg S, Theile CS, et al. Centyrin ligands for extrahepatic delivery of siRNA. Mol Ther. 2021;29:2053–2066.
   PubMed Web of Science ®Google Scholar
• Kubo T, Nishimura Y, Sato Y, et al. Sixteen different types of lipid-conjugated siRNAs containing saturated and unsaturated fatty acids and exhibiting enhanced RNAi potency. ACS Chem Biol. 2021;16:150–164.
   PubMed Web of Science ®Google Scholar
• Biscans A, Coles A, Echeverria D, et al. The valency of fatty acid conjugates impacts siRNA pharmacokinetics, distribution, and efficacy in vivo. J Control Release. 2019;302:116–125.
   PubMed Web of Science ®Google Scholar
• Osborn MF, Coles AH, Biscans A, et al. Hydrophobicity drives the systemic distribution of lipid-conjugated siRNAs via lipid transport pathways. Nucleic Acids Res. 2018;47:1070–1081.
   Web of Science ®Google Scholar
• Biscans A, Caiazzi J, McHugh N, et al. Docosanoic acid conjugation to siRNA enables functional and safe delivery to skeletal and cardiac muscles. Mol Ther. 2021;29:1382–1394.
   PubMed Web of Science ®Google Scholar
• Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat Biotechnol. 2017;35:222–229.
   PubMed Web of Science ®Google Scholar
• Good L, Awasthi SK, Dryselius R, et al. Bactericidal antisense effects of peptide-PNA conjugates. Nat Biotechnol. 2001;19:360–364.
   PubMed Web of Science ®Google Scholar
• Sully EK, Geller BL. Antisense antimicrobial therapeutics. Curr Opin Microbiol. 2016;33:47–55.
   PubMed Web of Science ®Google Scholar
• Geller BL, Li L, Martinez F, et al. Morpholino oligomers tested in vitro, in biofilm and in vivo against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother. 2018;73:1611–1619.
   PubMed Web of Science ®Google Scholar
• Dryselius R, Aswasti SK, Rajarao GK, et al. The translation start codon region is sensitive to antisense PNA inhibition in Escherichia coli. Oligonucleotides. 2003;13:427–433.
   PubMedGoogle Scholar
• Deere J, Iversen P, Geller BL. Antisense phosphorodiamidate morpholino oligomer length and target position effects on gene-specific inhibition in Escherichia coli. Antimicrob Agents Chemother. 2005;49:249–255.
   PubMed Web of Science ®Google Scholar
• Goltermann L, Yavari N, Zhang M, et al. PNA length restriction of antibacterial activity of Peptide-PNA conjugates in Escherichia coli through effects of the inner membrane. Front Microbiol. 2019;10:1032.
   PubMed Web of Science ®Google Scholar
• Daly SM, Sturge CR, Marshall-Batty KR, et al. Antisense inhibitors retain activity in pulmonary models of burkholderia infection. ACS Infect Dis. 2018;4(5):806–814.
   PubMed Web of Science ®Google Scholar
• Pfeiffer V, Papenfort K, Lucchini S, et al. Coding sequence targeting by MicC RNA reveals bacterial mRNA silencing downstream of translational initiation. Nat Struct Mol Biol. 2009;16(8):840–846.
   PubMed Web of Science ®Google Scholar
• Xue XY, Mao XG, Zhou Y, et al. Advances in the delivery of antisense oligonucleotides for combating bacterial infectious diseases. Nanomedicine. 2018;14(3):745–758.
   PubMed Web of Science ®Google Scholar
• Andrews JM. Determination of minimum inhibitory concentrations. J Antimicrob Chemother. 2001;48(1):5–16. Suppl.
   PubMedGoogle Scholar
• Greenberg DE, Marshall-Batty KR, Brinster LR, et al. Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J Infect Dis. 2010;201:1822–1830.
   PubMed Web of Science ®Google Scholar
• Howard JJ, Sturge CR, Moustafa DA, et al. Inhibition of Pseudomonas aeruginosa by peptide-conjugated phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother. 2017;61. DOI:10.1128/AAC.01938-16
   PubMed Web of Science ®Google Scholar
• Geller BL, Marshall-Batty K, Schnell FJ, et al. Gene-silencing antisense oligomers inhibit acinetobacter growth in vitro and in vivo. J Infect Dis. 2013;208:1553–1560.
   PubMed Web of Science ®Google Scholar
• Barkowsky G, Lemster AL, Pappesch R, et al. Influence of different cell-penetrating peptides on the antimicrobial efficiency of PNAs in Streptococcus pyogenes. Mol Ther Nucleic Acids. 2019;18:444–454.
   PubMedGoogle Scholar
• Puckett SE, Reese KA, Mitev GM, et al. Bacterial resistance to antisense peptide phosphorodiamidate morpholino oligomers. Antimicrob Agents Chemother. 2012;56:6147–6153.
   PubMed Web of Science ®Google Scholar
• Ghosal A, Vitali A, Stach JE, et al. Role of SbmA in the uptake of peptide nucleic acid (PNA)-peptide conjugates in E. coli. ACS Chem Biol. 2013;8:360–367.
   PubMed Web of Science ®Google Scholar
• Hansen AM, Bonke G, Larsen CJ, et al. Antibacterial peptide nucleic acid-antimicrobial peptide (PNA-AMP) conjugates: antisense targeting of fatty acid biosynthesis. Bioconjug Chem. 2016;27:863–867.
   PubMed Web of Science ®Google Scholar
• Li LC, Okino ST, Zhao H, et al. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci U S A. 2006;103:17337–17342.
   PubMed Web of Science ®Google Scholar
• Huang V, Qin Y, Wang J, et al. RNAa is conserved in mammalian cells. PLoS One. 2010;5:e8848.
   PubMed Web of Science ®Google Scholar
• Turunen MP, Lehtola T, Heinonen SE, et al. Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy. Circ Res. 2009;105:604–609.
   PubMed Web of Science ®Google Scholar
• Meng X, Jiang Q, Chang N, et al. Small activating RNA binds to the genomic target site in a seed-region-dependent manner. Nucleic Acids Res. 2016;44:2274–2282.
   PubMed Web of Science ®Google Scholar
• Voutila J, Reebye V, Roberts TC, et al. Development and mechanism of small activating RNA targeting CEBPA, a novel therapeutic in clinical trials for liver cancer. Mol Ther. 2017;25:2705–2714.
   PubMed Web of Science ®Google Scholar
• Place RF, Noonan EJ, Földes-Papp Z, et al. Defining features and exploring chemical modifications to manipulate RNAa activity. Curr Pharm Biotechnol. 2010;11:518–526.
   PubMed Web of Science ®Google Scholar
• Janowski BA, Younger ST, Hardy DB, et al. Activating gene expression in mammalian cells with promoter-targeted duplex RNAs. Nat Chem Biol. 2007;3:166–173.
   PubMed Web of Science ®Google Scholar
• Portnoy V, Lin SH, Li KH, et al. saRNA-guided Ago2 targets the RITA complex to promoters to stimulate transcription. Cell Res. 2016;26:320–335.
   PubMed Web of Science ®Google Scholar
• Chu Y, Yue X, Younger ST, et al. Involvement of argonaute proteins in gene silencing and activation by RNAs complementary to a non-coding transcript at the progesterone receptor promoter. Nucleic Acids Res. 2010;38:7736–7748.
   PubMed Web of Science ®Google Scholar
• Matsui M, Sakurai F, Elbashir S, et al. Activation of LDL receptor expression by small RNAs complementary to a noncoding transcript that overlaps the LDLR promoter. Chem Biol. 2010;17:1344–1355.
   PubMedGoogle Scholar
• Matsui M, Chu Y, Zhang H, et al. Promoter RNA links transcriptional regulation of inflammatory pathway genes. Nucleic Acids Res. 2013;41:10086–10109.
   PubMed Web of Science ®Google Scholar
• Zhang X, Li H, Burnett JC, et al. The role of antisense long noncoding RNA in small RNA-triggered gene activation. Rna. 2014;20:1916–1928.
   PubMed Web of Science ®Google Scholar
• Zhao X, Reebye V, Hitchen P, et al. Mechanisms involved in the activation of C/EBPα by small activating RNA in hepatocellular carcinoma. Oncogene. 2019;38:3446–3457.
   PubMed Web of Science ®Google Scholar
• Yoon S, Rossi JJ. Therapeutic potential of small activating RNAs (saRNAs) in human cancers. Curr Pharm Biotechnol. 2018;19:604–610.
   PubMed Web of Science ®Google Scholar
• Huang KW, Reebye V, Czysz K, et al. Liver activation of hepatocellular nuclear factor-4α by small activating RNA rescues dyslipidemia and improves metabolic profile. Mol Ther Nucleic Acids. 2020;19:361–370.
   PubMedGoogle Scholar
• Sarker D, Plummer R, Meyer T, et al. MTL-CEBPA, a small activating RNA therapeutic upregulating C/EBP-α, in patients with advanced liver cancer: a first-in-human, multicenter, open-label, phase i trial. Clin Cancer Res off J Am Assoc Cancer Res. 2020;26:3936–3946.
   PubMed Web of Science ®Google Scholar
• Ross JS, Sheehan CE, Fisher HAG, et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2003;9:6357–6362.
   PubMed Web of Science ®Google Scholar
• Silver DA, Pellicer I, Fair WR, et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res off J Am Assoc Cancer Res. 1997;3:81–85.
   PubMed Web of Science ®Google Scholar
• Seeman NC, Sleiman HF. DNA nanotechnology. Nat Rev Mater. 2017;3:17068.
   Web of Science ®Google Scholar
• Dey S, Fan C, Gothelf KV, et al. DNA origami. Nat Rev Method Primers. 2021;1:13.
   Google Scholar
• Tikhomirov G, Petersen P, Qian L. Fractal assembly of micrometre-scale DNA origami arrays with arbitrary patterns. Nature. 2017;552:67–71.
   PubMed Web of Science ®Google Scholar
• Benson E, Mohammed A, Gardell J, et al. DNA rendering of polyhedral meshes at the nanoscale. Nature. 2015;523:441–444.
   PubMed Web of Science ®Google Scholar
• Rothemund PWK. Folding DNA to create nanoscale shapes and patterns. Nature. 2006;440:297–302.
   PubMed Web of Science ®Google Scholar
• Andersen ES, Dong M, Nielsen MM, et al. DNA origami design of dolphin-shaped structures with flexible tails. ACS Nano. 2008;2:1213–1218.
   PubMed Web of Science ®Google Scholar
• Jun H, Shepherd TR, Zhang K, et al. Automated sequence design of 3d polyhedral wireframe DNA origami with honeycomb edges. ACS Nano. 2019;13:2083–2093.
   PubMed Web of Science ®Google Scholar
• Goodman RP, Berry RM, Turberfield AJ. The single-step synthesis of a DNA tetrahedron. Chem Comm. 2004;1372–1373. DOI:10.1039/b402293a
   PubMed Web of Science ®Google Scholar
• Aldaye FA, Sleiman HF. Modular access to structurally switchable 3D discrete DNA assemblies. J Am Chem Soc. 2007;129:13376–13377.
   PubMed Web of Science ®Google Scholar
• Hu Q, Li H, Wang L, et al. DNA nanotechnology-enabled drug delivery systems. Chem Rev. 2019;119:6459–6506.
   PubMed Web of Science ®Google Scholar
• Chidchob P, Sleiman HF. Recent advances in DNA nanotechnology. Curr Opin Chem Biol. 2018;46:63–70.
   PubMed Web of Science ®Google Scholar
• Afonin KA, Dobrovolskaia MA, Church G, et al. Opportunities, barriers, and a strategy for overcoming translational challenges to therapeutic nucleic acid nanotechnology. ACS Nano. 2020;14:9221–9227.
   PubMed Web of Science ®Google Scholar
• Bujold KE, Lacroix A, Sleiman HF. DNA nanostructures at the interface with biology. Chem. 2018;4:495–521.
   Web of Science ®Google Scholar
• Walsh AS, Yin H, Erben CM, et al. DNA cage delivery to mammalian cells. ACS Nano. 2011;5:5427–5432.
   PubMed Web of Science ®Google Scholar
• Mirkin CA, Letsinger RL, Mucic RC, et al. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature. 1996;382:607–609.
   PubMed Web of Science ®Google Scholar
• Cutler JI, Auyeung E, Mirkin CA. Spherical nucleic acids. J Am Chem Soc. 2012;134:1376–1391.
   PubMed Web of Science ®Google Scholar
• Liu B, Liu J. Methods for preparing DNA-functionalized gold nanoparticles, a key reagent of bioanalytical chemistry. Anal Methods. 2017;9:2633–2643.
   Web of Science ®Google Scholar
• Kapadia CH, Melamed JR, Day ES. Spherical Nucleic Acid Nanoparticles: therapeutic Potential. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy. 2018;32: 297–309.
   PubMed Web of Science ®Google Scholar
• Jiang S, Ge Z, and Mou S, et al. Designer DNA nanostructures for therapeutics. Chem. 2020;7: 1156–1179.
   Web of Science ®Google Scholar
• Wang S, Qin L, Yamankurt G, et al. Rational vaccinology with spherical nucleic acids. Proc Nat Acad Sci. 2019;116:10473–10481.
   PubMed Web of Science ®Google Scholar
• Zhang W, Meckes B, Mirkin CA. Spherical nucleic acids with tailored and active protein coronae. ACS Cent Sci. 2019;5:1983–1990.
   PubMed Web of Science ®Google Scholar
• Thai HBD, Kim K-R, Hong KT, et al. Kidney-targeted cytosolic delivery of siRNA using a small-sized mirror DNA tetrahedron for enhanced potency. ACS Cent Sci. 2020;6:2250–2258.
   PubMed Web of Science ®Google Scholar
• Lee H, Lytton-Jean AKR, Chen Y, et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat Nanotechnol. 2012;7:389–393.
   PubMed Web of Science ®Google Scholar
• Yamankurt G, Stawicki RJ, Posadas DM, et al. The effector mechanism of siRNA spherical nucleic acids. Proc Nat Acad Sci. 2020;117:1312–1320.
   PubMed Web of Science ®Google Scholar
• Rahman MA, Wang P, Zhao Z, et al. Systemic delivery of Bc12-Targeting siRNA by DNA nanoparticles suppresses cancer cell growth. Angew Chem. 2017;56:16023–16027.
   Google Scholar
• Kusmierz CD, Bujold KE, Callmann CE, et al. Defining the design parameters for in vivo enzyme delivery through protein spherical nucleic acids. ACS Cent Sci. 2020;6:815–822.
   PubMed Web of Science ®Google Scholar
• Lacroix A, Edwardson TGW, Hancock MA, et al. Development of DNA nanostructures for high-affinity binding to human serum albumin. J Am Chem Soc. 2017;139:7355–7362.
   PubMed Web of Science ®Google Scholar
• Zhao S, Tian R, Wu J, et al. A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis. Nat Commun. 2021;12:358.
   PubMed Web of Science ®Google Scholar
• Liu J, Song L, Liu S, et al. A DNA-based nanocarrier for efficient gene delivery and combined cancer therapy. Nano Lett. 2018;18:3328–3334.
   PubMed Web of Science ®Google Scholar
• Bujold KE, Hsu JCC, Sleiman HF. Optimized DNA “Nanosuitcases” for encapsulation and conditional release of siRNA. J Am Chem Soc. 2016;138:14030–14038.
   PubMed Web of Science ®Google Scholar
• You M, Peng L, Shao N, et al. DNA “Nano-Claw”: logic-based autonomous cancer targeting and therapy. J Am Chem Soc. 2014;136:1256–1259.
   PubMed Web of Science ®Google Scholar
• Fakih HH, Fakhoury JJ, Bousmail D, et al. Minimalist design of a stimuli-responsive spherical nucleic acid for conditional delivery of oligonucleotide therapeutics. ACS Appl Mater Interfaces. 2019;11:13912–13920.
   PubMed Web of Science ®Google Scholar
• Kim K-R, Kang SJ, Lee AY, et al. Highly tumor-specific DNA nanostructures discovered by in vivo screening of a nucleic acid cage library and their applications in tumor-targeted drug delivery. Biomaterials. 2019;195:1–12.
   PubMed Web of Science ®Google Scholar
• Yamankurt G, Berns EJ, Xue A, et al. Exploration of the nanomedicine-design space with high-throughput screening and machine learning. Nat Biomed Eng. 2019;3:318–327.
   PubMed Web of Science ®Google Scholar
• Veneziano R, Moyer TJ, Stone MB, et al. Role of nanoscale antigen organization on B-cell activation probed using DNA origami. Nat Nanotechnol. 2020;15:716–723.
   PubMed Web of Science ®Google Scholar
• Cremers GAO, Rosier BJHM, and Meijs A, et al. Determinants of Ligand-Functionalized DNA Nanostructure–Cell Interactions. J Am Chem Soc. 2021;143:10131–10142.
   PubMed Web of Science ®Google Scholar
• Leung K, Chakraborty K, Saminathan A, et al. A DNA nanomachine chemically resolves lysosomes in live cells. Nat Nanotechnol. 2019;14:176–183.
   PubMed Web of Science ®Google Scholar
• Samanta D, Ebrahimi SB, Kusmierz CD, et al. Protein spherical nucleic acids for live-cell chemical analysis. J Am Chem Soc. 2020;142:13350–13355.
   PubMed Web of Science ®Google Scholar
• Arulkumaran N, Lanphere C, Gaupp C, et al. DNA nanodevices with selective immune cell interaction and function. ACS Nano. 2021;15:4394–4404.
   PubMed Web of Science ®Google Scholar
• Ghimire C, Wang H, Li H, et al. RNA nanoparticles as rubber for compelling vessel extravasation to enhance tumor targeting and for fast renal excretion to reduce toxicity. ACS Nano. 2020;14:13180–13191.
   PubMed Web of Science ®Google Scholar
• Lacroix A, Sleiman HF. DNA nanostructures: current challenges and opportunities for cellular delivery. ACS Nano. 2021;15:3631–3645.
   PubMed Web of Science ®Google Scholar
• Chandrasekaran AR. Nuclease resistance of DNA nanostructures. Nat Rev Chem. 2021;5:225–239.
   PubMed Web of Science ®Google Scholar
• Kim K-R, Lee T, Kim B-S, et al. Utilizing the bioorthogonal base-pairing system of l-DNA to design ideal DNA nanocarriers for enhanced delivery of nucleic acid cargos. Chem Sci. 2014;5:1533–1537.
   Web of Science ®Google Scholar
• Ding H, Li J, Chen N, et al. DNA nanostructure-programmed like-charge attraction at the cell-membrane interface. ACS Cent Sci. 2018;4:1344–1351.
   PubMed Web of Science ®Google Scholar
• Gudipati S, Zhang K, Rouge JL. Towards self-transfecting nucleic acid nanostructures for gene regulation. Trends Biotechnol. 2019;37:983–994.
   PubMed Web of Science ®Google Scholar
• Guo S, Li H, Ma M, et al. Size, shape, and sequence-dependent immunogenicity of RNA nanoparticles. Mol Ther. 2017;9:399–408.
   Web of Science ®Google Scholar
• Zhang Q, Lin S, Shi S, et al. Anti-inflammatory and antioxidative effects of tetrahedral DNA nanostructures via the modulation of macrophage responses. ACS Appl Mater Interfaces. 2018;10:3421–3430.
   PubMed Web of Science ®Google Scholar
• Keller A, Linko V. Challenges and perspectives of DNA nanostructures in biomedicine. Angew Chem. 2020;59:15818–15833.
   Google Scholar
• Hill AC, Bartley LE, Schroeder SJ. Prohead RNA: a noncoding viral RNA of novel structure and function. WIREs RNA. 2016;7:428–437.
   Google Scholar
• Smith DE, Tans SJ, Smith SB, et al. The bacteriophage straight phi29 portal motor can package DNA against a large internal force. Nature. 2001;413:748–752.
   PubMed Web of Science ®Google Scholar
• Mao H, Saha M, Reyes-Aldrete E, et al. Structural and molecular basis for coordination in a viral DNA packaging motor. Cell Rep. 2016;14:2017–2029.
   PubMed Web of Science ®Google Scholar
• Guo PX, Erickson S, Anderson D. A small viral RNA is required for in vitro packaging of bacteriophage phi 29 DNA. Science. 1987;236:690–694.
   PubMed Web of Science ®Google Scholar
• Gilbert W. Origin of life: the RNA world. Nature. 1986;319:618.
   PubMed Web of Science ®Google Scholar
• Bailey S, Wichitwechkarn J, Johnson D, et al. Phylogenetic analysis and secondary structure of the Bacillus subtilis bacteriophage RNA required for DNA packaging. J Biol Chem. 1990;265:22365–22370.
   PubMed Web of Science ®Google Scholar
• Guo P, Zhang C, Chen C, et al. Inter-RNA interaction of phage φ29 pRNA to form a hexameric complex for viral DNA transportation. Mol Cell. 1998;2:149–155.
   PubMed Web of Science ®Google Scholar
• Gu X, Schroeder SJ. Different sequences show similar quaternary interaction stabilities in prohead viral RNA self-assembly. J Biol Chem. 2011;286:14419–14426.
   PubMed Web of Science ®Google Scholar
• Hao Y, Kieft JS. Diverse self-association properties within a family of phage packaging RNAs. RNA. 2014;20:1759–1774.
   PubMed Web of Science ®Google Scholar
• Hill AC, Schroeder SJ. Thermodynamic stabilities of three-way junction nanomotifs in prohead RNA. RNA. 2017;23:521–529.
   PubMed Web of Science ®Google Scholar
• Hao Y, Kieft JS. Three-way junction conformation dictates self-association of phage packaging RNAs. RNA Biol. 2016;13:635–645.
   PubMed Web of Science ®Google Scholar
• Guo P. The emerging field of RNA nanotechnology. Nat Nanotechnol. 2010;5:833–842.
   PubMed Web of Science ®Google Scholar
• Jasinski D, Haque F, Binzel DW, et al. Advancement of the emerging field of RNA nanotechnology. ACS Nano. 2017;11:1142–1164.
   PubMed Web of Science ®Google Scholar
• Hill AC, Hall J. High-order structures from nucleic acids for biomedical applications. Mater Chem Front. 2020;4:1074–1088.
   Web of Science ®Google Scholar
• Guo S, Tschammer N, Mohammed S, et al. Specific delivery of therapeutic RNAs to cancer cells via the dimerization mechanism of phi29 motor pRNA. Hum Gene Ther. 2005;16:1097–1109.
   PubMed Web of Science ®Google Scholar
• Khaled A, Guo S, Li F, et al. Controllable self-assembly of nanoparticles for specific delivery of multiple therapeutic molecules to cancer cells using RNA nanotechnology. Nano Lett. 2005;5:1797–1808.
   PubMed Web of Science ®Google Scholar
• Zhang HM, Su Y, Guo S, et al. Targeted delivery of anti-coxsackievirus siRNAs using ligand-conjugated packaging RNAs. Antiviral Res. 2009;83:307–316.
   PubMed Web of Science ®Google Scholar
• Tarapore P, Shu Y, Guo P, et al. Application of phi29 motor pRNA for targeted therapeutic delivery of siRNA silencing metallothionein-IIA and survivin in ovarian cancers. Mol Ther. 2011;19:386–394.
   PubMed Web of Science ®Google Scholar
• Shu D, Shu Y, Haque F, et al. Thermodynamically stable RNA three-way junction for constructing multifunctional nanoparticles for delivery of therapeutics. Nat Nanotechnol. 2011;6:658–667.
   PubMed Web of Science ®Google Scholar
• Abdelmawla S, Guo S, Zhang L, et al. Pharmacological characterization of chemically synthesized monomeric phi29 pRNA nanoparticles for systemic delivery. Mol Ther. 2011;19:1312–1322.
   PubMed Web of Science ®Google Scholar
• Lee TJ, Haque F, Shu D, et al. RNA nanoparticle as a vector for targeted siRNA delivery into glioblastoma mouse model. Oncotarget. 2015;6:14766–14776.
   PubMedGoogle Scholar
• Cui D, Zhang C, Liu B, et al. Regression of gastric cancer by systemic injection of RNA nanoparticles carrying both ligand and siRNA. Sci Rep. 2015;5:10726.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Leonard M, Shu Y, et al. Overcoming tamoxifen resistance of human breast cancer by targeted gene silencing using multifunctional pRNA nanoparticles. ACS Nano. 2017;11:335–346.
   PubMed Web of Science ®Google Scholar
• Xu Y, Pang L, Wang H, et al. Specific delivery of delta-5-desaturase siRNA via RNA nanoparticles supplemented with dihomo-γ-linolenic acid for colon cancer suppression. Redox Biol. 2019;21:101085.
   PubMed Web of Science ®Google Scholar
• Setten RL, Rossi JJ, Han S-P. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421–446.
   PubMed Web of Science ®Google Scholar
• Shen W, De Hoyos CL, Migawa MT, et al. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index. Nat Biotechnol. 2019;37:640–650.
   PubMed Web of Science ®Google Scholar
• Grimm D, Streetz KL, Jopling CL, et al. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature. 2006;441:537–541.
   PubMed Web of Science ®Google Scholar
• Wang Y, Vorperian A, Shehabat M, et al. Evaluating the catalytic potential of a general RNA-cleaving FANA enzyme. Chembiochem. 2020;21:1001–1006.
   PubMed Web of Science ®Google Scholar
• Ghidini A, Murtola M, Strömberg R. DNA in Supramolecular Chemistry and Nanotechnology. 2014;158–171.
   Google Scholar
• Niittymäki T, Lönnberg H. Artificial ribonucleases. Org Biomol Chem. 2006;4:15–25.
   PubMed Web of Science ®Google Scholar
• Akinori K, Makoto K. Site-selective artificial ribonucleases and their applications. Curr Org Chem. 2007;11:1450–1459.
   Web of Science ®Google Scholar
• Kaukinen U, Bielecki L, Mikkola S, et al. The cleavage of phosphodiester bonds within small RNA bulges in the presence and absence of metal ion catalysts Journal of the Chemical Society. Perkin Transac. 2001;2:1024–1031.
   Google Scholar
• Hüsken D, Goodall G, Blommers MJ, et al. Creating RNA bulges: cleavage of RNA in RNA/DNA duplexes by metal ion catalysis. Biochemistry. 1996;35:16591–16600.
   PubMed Web of Science ®Google Scholar
• Aström H, Williams NH, Strömberg R. Oligonucleotide based artificial nuclease (OBAN) systems. Bulge size dependence and positioning of catalytic group in cleavage of RNA-bulges. Org Biomol Chem. 2003;1:1461–1465.
   PubMed Web of Science ®Google Scholar
• Magda D, Wright M, Crofts S, et al. Metal complex conjugates of antisense DNA which display ribozyme-like activity. J Am Chem Soc. 1997;119:6947–6948.
   Web of Science ®Google Scholar
• Dogandzhiyski P, Ghidini A, Danneberg F, et al. Studies on tris(2-aminobenzimidazole)-PNA based artificial nucleases: a comparison of two analytical techniques. Bioconjug Chem. 2015;26:2514–2519.
   PubMed Web of Science ®Google Scholar
• Zellmann F, Thomas L, Scheffer U, et al. Site-specific cleavage of RNAs derived from the PIM1 3’-UTR by a metal-free artificial ribonuclease. Molecules. 2019;24:807.
   PubMed Web of Science ®Google Scholar
• Zellmann F, Göbel MW. A trisbenzimidazole phosphoramidite building block enables high-yielding syntheses of RNA-cleaving oligonucleotide conjugates. Molecules. 2020;25:1842.
   PubMed Web of Science ®Google Scholar
• Staroseletz Y, Amirloo B, Williams A, et al. Strict conformational demands of RNA cleavage in bulge-loops created by peptidyl-oligonucleotide conjugates. Nucleic Acids Res. 2020;48:10662–10679.
   PubMed Web of Science ®Google Scholar
• Patutina OA, Miroshnichenko SK, Mironova NL, et al. Catalytic knockdown of miR-21 by artificial ribonuclease: biological performance in tumor model. Front Pharmacol. 2019;10:879.
   PubMed Web of Science ®Google Scholar
• Patutina O, Chiglintseva D, Bichenkova E, et al. Dual miRNases for triple incision of miRNA target: design concept and catalytic performance. Molecules. 2020;25:2459.
   PubMed Web of Science ®Google Scholar
• Murtola M, Wenska M, Stroemberg R. PNAzymes that are artificial RNA restriction enzymes. J Am Chem Soc. 2010;132:8984–8990.
   PubMed Web of Science ®Google Scholar
• Luige O, Murtola M, Ghidini A, et al. Further probing of Cu(2+)-dependent PNAzymes acting as artificial RNA restriction enzymes. Molecules. 2019;24:672.
   PubMed Web of Science ®Google Scholar
• Ghidini A, Murtola M, Stroemberg R. Influence of conjugation and other structural changes on the activity of Cu2+ based PNAzymes. Org Biomol Chem. 2016;14:2768–2773.
   PubMed Web of Science ®Google Scholar
• Murtola M, Virta P, Murtola M, et al. Zinc ion-dependent peptide nucleic acid-based artificial enzyme that cleaves RNA-bulge size and sequence dependence. Molecules. 2017;22:1856.
   PubMed Web of Science ®Google Scholar
• Pettersson M, Crews CM. PROteolysis targeting chimeras (PROTACs) — past, present and future. Drug Discov Today. 2019;31:15–27.
   Google Scholar
• Kocaturk NM, Gozuacik D. Crosstalk between mammalian autophagy and the ubiquitin-proteasome system. Front Cell Dev Biol. 2018;6:128.
   PubMed Web of Science ®Google Scholar
• Lai AC, Crews CM. Induced protein degradation: an emerging drug discovery paradigm. Nat Rev Drug Discov. 2017;16:101–114.
   PubMed Web of Science ®Google Scholar
• Smith BE, Wang SL, Jaime-Figueroa S, et al. Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase. Nat Commun. 2019;10:131.
   PubMed Web of Science ®Google Scholar
• Flanagan JJ, Neklesa TK. Targeting nuclear receptors with PROTAC degraders. Mol Cell Endocrinol. 2019;493:110452.
   PubMed Web of Science ®Google Scholar
• Sun X, Gao H, Yang Y, et al. PROTACs: great opportunities for academia and industry. Signal Transduct Target Ther. 2019;4:64.
   PubMed Web of Science ®Google Scholar
• Burslem GM, Crews CM. Proteolysis-targeting chimeras as therapeutics and tools for biological discovery. Cell. 2020;181:102–114.
   PubMed Web of Science ®Google Scholar
• Ghidini A, Cléry A, Halloy F, et al. RNA-PROTACs: degraders of RNA-binding proteins. Angew Chem. 2021;60:3163–3169.
   Google Scholar
• Samarasinghe KTG, Jaime-Figueroa S, Burgess M, et al. Targeted degradation of transcription factors by TRAFTACs: transcription factor targeting chimeras. Cell Chem Biol. 2021;28:648–661.
   PubMed Web of Science ®Google Scholar
• Shao J, Yan Y, and Ding D, et al. Destruction of DNA-binding proteins by programmable oligonucleotide PROTAC (O’PROTAC): effective targeting of LEF1 and ERG. Advanced Science. N/a. 2021;8:e2102555–e2102555.
   Web of Science ®Google Scholar
• Maneiro M, Forte N, Shchepinova MM, et al. Antibody-PROTAC conjugates enable HER2-dependent targeted protein degradation of BRD4. ACS Chem Biol. 2020;15:1306–1312.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen H, Ma L, et al. Light-induced control of protein destruction by opto-PROTAC. Sci Adv. 2020;6:eaay5154.
   PubMed Web of Science ®Google Scholar
• Reynders M, Matsuura BS, Bérouti M, et al. PHOTACs enable optical control of protein degradation. Sci Adv. 2020;6:eaay5064.
   PubMed Web of Science ®Google Scholar
• Banik SM, Pedram K, Wisnovsky S, et al. Lysosome-targeting chimaeras for degradation of extracellular proteins. Nature. 2020;584:291–297.
   PubMed Web of Science ®Google Scholar
• Gaudet D, Digenio A, Alexander VJ, et al. The APPROACH study: a randomized, double-blind, placebo-controlled, phase 3 study of volanesorsen administered subcutaneously to patients with familial chylomicronemia syndrome (FCS). J Clin Lipidol. 2017;11:814–815.
   Google Scholar